Blair William & Co. IL Reduces Stake in Hologic, Inc. (NASDAQ:HOLX)

Blair William & Co. IL cut its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 42.9% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 141,287 shares of the medical equipment provider’s stock after selling 106,111 shares during the period. Blair William & Co. IL owned 0.06% of Hologic worth $10,185,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. General Partner Inc. purchased a new position in Hologic during the 4th quarter valued at $26,000. Groupama Asset Managment increased its position in shares of Hologic by 9.9% during the third quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 2,999 shares during the period. Venturi Wealth Management LLC increased its position in shares of Hologic by 156.3% during the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock valued at $31,000 after buying an additional 261 shares during the period. EverSource Wealth Advisors LLC raised its stake in Hologic by 79.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider’s stock worth $42,000 after buying an additional 260 shares in the last quarter. Finally, Smartleaf Asset Management LLC boosted its position in Hologic by 36.9% during the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock valued at $43,000 after acquiring an additional 159 shares in the last quarter. Institutional investors own 94.73% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on HOLX. Morgan Stanley decreased their target price on Hologic from $84.00 to $82.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. Jefferies Financial Group began coverage on Hologic in a report on Tuesday, December 10th. They issued a “hold” rating and a $85.00 price objective for the company. William Blair restated an “outperform” rating on shares of Hologic in a report on Thursday, February 6th. BNP Paribas upgraded shares of Hologic to a “strong-buy” rating in a research note on Tuesday, December 10th. Finally, Needham & Company LLC cut shares of Hologic from a “buy” rating to a “hold” rating and set a $90.00 price target for the company. in a research report on Monday, February 3rd. Eleven investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $84.62.

Hologic Stock Down 1.6 %

Hologic stock opened at $61.32 on Friday. Hologic, Inc. has a 12 month low of $60.34 and a 12 month high of $84.67. The stock has a fifty day simple moving average of $65.24 and a two-hundred day simple moving average of $73.29. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. The firm has a market cap of $13.76 billion, a price-to-earnings ratio of 19.34, a PEG ratio of 2.14 and a beta of 0.97.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. Equities analysts predict that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.